Name (Synonyms) | Correlation | |
---|---|---|
drug2018 | PB1046 Wiki | 0.71 |
drug3236 | convalescent plasma application to SARS-CoV-2 infected patients Wiki | 0.71 |
drug1609 | Low Dose (10 mg) Control Wiki | 0.71 |
drug916 | Dornase Alfa Inhalation Solution Wiki | 0.71 |
drug313 | Azithromycin Wiki | 0.12 |
drug1284 | Hydroxychloroquine Wiki | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
D011654 | Pulmonary Edema NIH | 0.50 |
D011665 | Pulmonary Valve Insufficiency NIH | 0.27 |
D006333 | Heart Failure NIH | 0.24 |
D007249 | Inflammation NIH | 0.14 |
D013577 | Syndrome NIH | 0.07 |
D055371 | Acute Lung Injury NIH | 0.07 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.07 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.06 |
D003141 | Communicable Diseases NIH | 0.06 |
D011014 | Pneumonia NIH | 0.04 |
D007239 | Infection NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100598 | Pulmonary edema HPO | 0.50 |
HP:0010444 | Pulmonary insufficiency HPO | 0.27 |
HP:0001635 | Congestive heart failure HPO | 0.24 |
HP:0002090 | Pneumonia HPO | 0.04 |
There are 2 clinical trials
This project investigates individual treatments using convalescent severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) plasma in SARS-CoV-2 infected patients at risk for disease progression. In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma. Only patients with moderate to severe disease at risk for transfer to intensive care unit or patients at the intensive care unit with limited treatment options will be treated.
Description: Serious adverse events during the study period include transfusion reaction (fever, rash), transfusion related acute lung injury (TRAU) , transfusion associated circulatory overload (TACO) , transfusion related infection
Measure: Serious adverse events in convalescent plasma treated patients Time: From baseline (enrolment) to 24 hours follow-upDescription: Change in SARS-CoV2 quantitative in nasopharyngeal swab
Measure: Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28Description: Transfer to ICU
Measure: Transfer to ICU Time: at Baseline (admission to Covid-ward) until day 28Description: in-hospital death
Measure: in-hospital death Time: at Baseline (admission to Covid-ward) until day 28Description: Change in SARS-CoV2 quantitative in plasma
Measure: Virologic clearance in plasma of convalescent plasma treated patients Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28Description: Duration of hospitalisation
Measure: Time to discharge from hospital after enrolment Time: at Baseline (admission to Covid-ward) until discharge (approx. 28 days)Description: Rise of SARS-CoV-2 antibody titers (on day 1, 7, 14 and 28)
Measure: Humoral immune response Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of PB1046 by improving the clinical outcomes and increasing days alive and free of respiratory failure in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.
Description: PaO2:FiO2 ratio is the ratio of partial pressure of arterial oxygen to percentage of inspired oxygen
Measure: Development of ARDS (PaO2:FiO2 ratio < 300 mm Hg) during hospitalization Time: Any time point between injection initiation and Day 28Description: Composite of: Total hospital days, Total ICU days, Total days of ventilator use, Total days of ECMO, Total days of invasive hemodynamic monitoring, Total days of mechanical circulatory support, Total days of inotropic or vasopressor therapy
Measure: Reduction in hospital resource utilization defined as a composite of:total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy Time: 28 days